Puma Biotechnology (PBYI) Stock Analysis & AI Equity Report
Puma Biotechnology (PBYI) overview
Puma Biotechnology (PBYI) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 228m and operating profit of USD 37.3m; the year-end share price was 5.95 USD and market capitalisation was USD 300m. Puma Biotechnology is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Puma Biotechnology's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Puma Biotechnology
Puma Biotechnology develops and commercializes products for cancer treatment. Its commercial product, NERLYNX, is an oral form of neratinib approved in the United States for certain early-stage and advanced or metastatic HER2-positive breast cancers. The company also holds global development and commercialization rights to alisertib, an investigational small-molecule inhibitor being developed initially for small cell lung cancer and hormone receptor-positive breast cancer.
Generate the Puma Biotechnology report
Puma Biotechnology is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Puma Biotechnology and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Puma Biotechnology
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.